Spironolactone لـ تساقط الشعر النمطي الأنثوي
A الأدلة تُظهر تجارب سريرية كبيرة متعددة باستمرار فوائد ملحوظة.بناءً على 19 دراسة (2 meta-analyses, 4 RCTs) بمشاركة 5,743 مشاركًا إجمالاً. 16/19 دراسة تُظهر تأثيرات إيجابية.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'haircited.com';
const params = 'ingredient\u003Dspironolactone\u0026condition\u003Dfemale\u002Dpattern\u002Dhair\u002Dloss';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
A
الخلاصة
Spironolactone is strongly supported by research as an effective option that may help women with female pattern hair loss, with both oral and topical formulations showing benefits in clinical trials.
- 84% of studies show positive effects, including 4 RCTs focused on women
- Both oral and topical formulations have demonstrated benefits
- A dedicated meta-analysis confirms efficacy and safety in female pattern hair loss
- Combination with minoxidil may offer enhanced results
Key Study Findings
Randomized Controlled Trial
n=204
24 weeks
Double-blind
Spironolactone versus Bicalutamide in female pattern hair loss: A randomised clinical trial.
Dose: Bicalutamide 50 mg/day; spironolactone 100 mg/day
مقابل: Spironolactone 100 mg/day
Outcome: Hair density and shaft diameter change at 24 …
التأثير: Frontal: +5.05 vs +3.13 hairs/cm2 (diff 1.92)
P < 0.001 (frontal); P = 0.028
المجتمع المدروس: Women 18-50 with Sinclair Grade II-V FPHL (India)
Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None
مقابل: None
Outcome: None
التأثير: None
None
المجتمع المدروس: women with androgenetic alopecia (female pattern hair loss)
randomized controlled trial
n=80
24 weeks
Single-blind
Evaluation of the Efficacy and Safety of Topical Spironolactone versus Topical Minoxidil in the Treatment …
Dose: Group A: 1% topical spironolactone gel twice daily; Group B: 5% topical minoxidil gel twice daily
مقابل: Placebo
التأثير: Both groups showed statistically significant improvement. Group A: 10 mild, 16 moderate, 2 excellent
None
RCT
n=48
24 weeks
Double-blind
Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a …
Dose: Spironolactone 100 mg once daily
مقابل: Placebo
التأثير: Terminal hair counts: 9.48 vs 5.32 hairs/cm2; hair diameter: 4.23 vs 2.96 μm; moderate-to-marked imp
p=0.063 (terminal hair counts)
randomized controlled trial
n=45
16 weeks
Open-label
Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in …
Dose: Group A: topical finasteride 1% solution; Group B: topical spironolactone 5% solution; Group C: topi
مقابل: Placebo
التأثير: Groups A and C showed significant improvement on Sinclair scale and trichoscopic hair density; Group
None
Key Statistics
45
الدراسات
6441
المشاركون
↑
Positive
A
التقييم
Referenced Papers
Clinical and experimental …
2026
American journal of …
2026
The British journal …
2025
10 اقتباسات
Journal of the …
2025
3 اقتباسات
International journal of …
2025
3 اقتباسات
Australian prescriber
2025
2 اقتباسات
Dermatology practical & …
2025
1 اقتباسات
International journal of …
2025
Frontiers in veterinary …
2024
15 اقتباسات
Journal of cosmetic …
2024
14 اقتباسات
Journal of clinical …
2024
11 اقتباسات
The Australasian journal …
2024
5 اقتباسات
Archives of dermatological …
2024
4 اقتباسات
Food and chemical …
2024
1 اقتباسات
JAAD international
2024
1 اقتباسات
Cureus
2023
13 اقتباسات
Journal of cosmetic …
2023
3 اقتباسات
Journal of personalized …
2022
16 اقتباسات
Frontiers in medicine
2022
14 اقتباسات
PEC innovation
2022
11 اقتباسات
Journal of the …
2020
43 اقتباسات
Clinical and experimental …
2020
20 اقتباسات
Dermatology practical & …
2020
10 اقتباسات
Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee.
Meta-Analysis
The Journal of …
2019
101 اقتباسات
Journal of the …
2019
95 اقتباسات
Journal of the …
2019
55 اقتباسات
Breast cancer research …
2019
36 اقتباسات
Polski merkuriusz lekarski …
2019
4 اقتباسات
Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone.
Observational
International journal of …
2018
142 اقتباسات
International journal of …
2018
129 اقتباسات
Australian journal of …
2018
8 اقتباسات
Interventions for female pattern hair loss.
Meta-Analysis
The Cochrane database …
2016
18 اقتباسات
The Medical clinics …
2015
66 اقتباسات
Journal of the …
2015
50 اقتباسات
Demographics of women with female pattern hair loss and the effectiveness of spironolactone therapy.
Other
Journal of the …
2015
43 اقتباسات
Hair loss in women.
Review
Clinical obstetrics and …
2015
9 اقتباسات
Female pattern hair loss.
Review
Current problems in …
2015
8 اقتباسات
Der Hautarzt; Zeitschrift …
2013
19 اقتباسات
International journal of …
2013
The British journal …
2011
96 اقتباسات
The Australasian journal …
2011
44 اقتباسات
Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss.
Other
Dermatologic clinics
2010
80 اقتباسات
Skinmed
2010
33 اقتباسات
Successful treatment of female-pattern hair loss with spironolactone in a 9-year-old girl.
Case Report
The Australasian journal …
2009
31 اقتباسات
Hair loss in women.
Review
Seminars in cutaneous …
2009
4 اقتباسات
Harvard women's health …
2009
Dermatology online journal
2008
Treatment of female pattern hair loss with a combination of spironolactone and minoxidil.
Case Report
The Australasian journal …
2007
32 اقتباسات
Duodecim; laaketieteellinen aikakauskirja
2006
Journal of the …
2005
247 اقتباسات
The British journal …
2005
205 اقتباسات
Journal of the …
2005
64 اقتباسات
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
الجرعات الشائعة
- hairloss:
- 100-200 mg/day (prescription)
الحد الأعلى: 200 mg/day (hair loss indication)
الجرعات المدروسة في الأبحاث
| الجرعة | المدة | التأثير | ن |
|---|---|---|---|
| Bicalutamide 50 mg/day; spironolactone 100 mg/day | 24 weeks | Positive | 204 |
| None | -- | Neutral | -- |
| Group A: 1% topical spironolactone gel twice daily; Group B: 5% topical minoxidil gel twice daily | 24 weeks | Positive | 80 |
| Spironolactone 100 mg once daily | 24 weeks | Positive | 48 |
| None | -- | Positive | -- |
| Group A: topical finasteride 1% solution; Group B: topical spironolactone 5% solution; Group C: topi | 16 weeks | Positive | 45 |
| None | 520 weeks | Positive | 240 |
| 4 g | -- | Neutral | -- |
أفضل وقت للتناول: Once or twice daily with food; prescription required
Safety & Side Effects
الآثار الجانبية المُبلّغ عنها
- ⚠ Menstrual irregularities
- ⚠ Breast tenderness
- ⚠ Hyperkalemia (elevated potassium levels)
- ⚠ Dizziness and orthostatic hypotension
- ⚠ Frequent urination
التفاعلات المعروفة
- ● ACE inhibitors and ARBs (increased hyperkalemia risk)
- ● Potassium supplements and potassium-sparing diuretics (dangerous hyperkalemia)
- ● NSAIDs (may reduce diuretic effectiveness and increase kidney risk)
- ● Digoxin (spironolactone may increase digoxin levels)
الحد الأقصى المسموح به: 200 mg/day (hair loss indication)
استشر مقدم الرعاية الصحية دائماً قبل البدء بأي مكمل غذائي.
Frequently Asked Questions
Does Spironolactone help with تساقط الشعر النمطي الأنثوي?
Based on 45 studies with 6,441 participants, there is strong evidence from multiple clinical trials that Spironolactone may support تساقط الشعر النمطي الأنثوي management. Our evidence grade is A (Strong Evidence).
How much Spironolactone should I take for تساقط الشعر النمطي الأنثوي?
Studies have used various dosages. A commonly studied range is 100-200 mg/day (prescription). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Spironolactone?
Reported side effects may include Menstrual irregularities, Breast tenderness, Hyperkalemia (elevated potassium levels), Dizziness and orthostatic hypotension. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Spironolactone and تساقط الشعر النمطي الأنثوي?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 45 peer-reviewed studies with 6,441 total participants. The overall direction of effect is positive.
Related Evidence
مكونات أخرى لـ تساقط الشعر النمطي الأنثوي
Spironolactone لحالات أخرى
References
- [1] Abhijeet Kumar Jha et al.. Clin Exp Dermatol. 2026. Spironolactone versus Bicalutamide in female pattern hair loss: A randomised clinical trial. doi:10.1093/ced/llag099 PubMed
- [2] Caitlin A Kearney et al.. Am J Clin Dermatol. 2026. Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments. doi:10.1007/s40257-026-01009-2 PubMed
- [3] Ilmari Saarinen et al.. Br J Surg. 2025. Nutritional deficiencies after sleeve gastrectomy and Roux-en-Y gastric bypass at 10 years: secondary analysis of the SLEEVEPASS randomized clinical trial. doi:10.1093/bjs/znaf132 PubMed
- [4] Juan Jimenez-Cauhe et al.. J Am Acad Dermatol. 2025. Spironolactone reduces the risk of low-dose oral minoxidil-induced edema in women with female pattern hair loss. doi:10.1016/j.jaad.2024.12.048 PubMed
- [5] Pimpakarn Werachattawatchai et al.. Int J Womens Dermatol. 2025. Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a randomized, double-blind, placebo-controlled, parallel-group pilot … doi:10.1097/JW9.0000000000000227 PubMed
- [6] Laxmi Iyengar et al.. Aust Prescr. 2025. Male and female pattern hair loss. doi:10.18773/austprescr.2025.020 PubMed
- [7] Naglaa Mohamad Al Sayed et al.. Dermatol Pract Concept. 2025. Clinical and Trichoscopic Evaluations of Topical Finasteride 1%, Topical Spironolactone 5%, and Minoxidil 5% in Female Pattern Hair Loss Treatment. doi:10.5826/dpc.1501a4698 PubMed
- [8] Ghada Fawzy Rezk Hassan et al.. Int J Trichology. 2025. Evaluation of the Efficacy and Safety of Topical Spironolactone versus Topical Minoxidil in the Treatment of Female Pattern Hair Loss: … doi:10.4103/ijt.ijt_118_23 PubMed
- [9] Sasithorn Limsuwan et al.. Front Vet Sci. 2024. Pharmacokinetics behavior of four cannabidiol preparations following single oral administration in dogs. doi:10.3389/fvets.2024.1389810 PubMed
- [10] Afsaneh Sadeghzadeh Bazargan et al.. J Cosmet Dermatol. 2024. The efficacy of the combination of topical minoxidil and oral spironolactone compared with the combination of topical minoxidil and oral … doi:10.1111/jocd.15979 PubMed
- [11] S Morteza Seyed Jafari et al.. J Clin Med. 2024. Safety of Antiandrogens for the Treatment of Female Androgenetic Alopecia with Respect to Gynecologic Malignancies. doi:10.3390/jcm13113052 PubMed
- [12] Abhijeet Kumar Jha et al.. Australas J Dermatol. 2024. Efficacy and safety of spironolactone versus bicalutamide in female pattern hair loss: A retrospective comparative study. doi:10.1111/ajd.14306 PubMed
- [13] Deesha D Desai et al.. Arch Dermatol Res. 2024. Comparative analysis of low-dose oral minoxidil with spironolactone versus finasteride or dutasteride in female androgenetic alopecia management. doi:10.1007/s00403-024-03361-x PubMed
- [14] Laura E Ewing et al.. Food Chem Toxicol. 2024. Inter-strain variability in responses to a single administration of the cannabidiol-rich cannabis extract in mice. doi:10.1016/j.fct.2024.114909 PubMed
- [15] Ambika Nohria et al.. JAAD Int. 2024. Improving efficacy and maintaining safety in the treatment of alopecia with low-dose oral minoxidil and spironolactone combination therapy: A retrospective … doi:10.1016/j.jdin.2024.07.023 PubMed
- [16] Majed Aleissa. Cureus. 2023. The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Pattern Hair Loss: A Systematic Review and Meta-Analysis. doi:10.7759/cureus.43559 PubMed
- [17] Shreya Deoghare et al.. J Cosmet Laser Ther. 2023. Combination therapy in female pattern hair loss. doi:10.1080/14764172.2023.2222942 PubMed
- [18] Marko Kumric et al.. J Pers Med. 2022. Chronic Effects of Effective Oral Cannabidiol Delivery on 24-h Ambulatory Blood Pressure and Vascular Outcomes in Treated and Untreated Hypertension … doi:10.3390/jpm12071037 PubMed
- [19] Xuelei Liang et al.. Front Med (Lausanne). 2022. Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: … doi:10.3389/fmed.2022.905140 PubMed
- [20] Pravesh Sharma et al.. PEC Innov. 2022. Primary care provider attitudes, experiences and practices about cannabidiol (CBD) and barriers to patient-provider communication about CBD use: A qualitative … doi:10.1016/j.pecinn.2022.100044 PubMed
- [21] Laura J Burns et al.. J Am Acad Dermatol. 2020. Spironolactone for treatment of female pattern hair loss. doi:10.1016/j.jaad.2020.03.087 PubMed
- [22] T N Searle et al.. Clin Exp Dermatol. 2020. Spironolactone in dermatology: uses in acne and beyond. doi:10.1111/ced.14340 PubMed
- [23] Alfredo Rossi et al.. Dermatol Pract Concept. 2020. Efficacy of Topical Finasteride 0.5% vs 17α-Estradiol 0.05% in the Treatment of Postmenopausal Female Pattern Hair Loss: A Retrospective, Single-Blind … doi:10.5826/dpc.1002a39 PubMed
- [24] Enrico Carmina et al.. J Clin Endocrinol Metab. 2019. Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. doi:10.1210/jc.2018-02548 PubMed
- [25] Amanda Bienenfeld et al.. J Am Acad Dermatol. 2019. Androgens in women: Androgen-mediated skin disease and patient evaluation. doi:10.1016/j.jaad.2018.08.062 PubMed
- [26] Sarah Azarchi et al.. J Am Acad Dermatol. 2019. Androgens in women: Hormone-modulating therapies for skin disease. doi:10.1016/j.jaad.2018.08.061 PubMed
- [27] Raquel N Rozner et al.. Breast Cancer Res Treat. 2019. Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies. doi:10.1007/s10549-018-4996-3 PubMed
- [28] Karolina Kozicka et al.. Pol Merkur Lekarski. 2019. Methods of treatment patients with androgenetic alopecia based on reference of Department of Dermatology in Cracow. PubMed
- [29] Rodney D Sinclair. Int J Dermatol. 2018. Female pattern hair loss: a pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. doi:10.1111/ijd.13838 PubMed
- [30] G Fabbrocini et al.. Int J Womens Dermatol. 2018. Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. doi:10.1016/j.ijwd.2018.05.001 PubMed
- [31] Linda Chan et al.. Aust J Gen Pract. 2018. Female pattern hair loss. doi:10.31128/AJGP-02-18-4498 PubMed
- [32] Esther J van Zuuren et al.. Cochrane Database Syst Rev. 2016. Interventions for female pattern hair loss. doi:10.1002/14651858.CD007628.pub4 PubMed
- [33] Jay C Vary. Med Clin North Am. 2015. Selected Disorders of Skin Appendages--Acne, Alopecia, Hyperhidrosis. doi:10.1016/j.mcna.2015.07.003 PubMed
- [34] Timothy H Schmidt et al.. J Am Acad Dermatol. 2015. Evidence-based approach to cutaneous hyperandrogenism in women. doi:10.1016/j.jaad.2015.05.026 PubMed
- [35] Shannon Famenini et al.. J Am Acad Dermatol. 2015. Demographics of women with female pattern hair loss and the effectiveness of spironolactone therapy. doi:10.1016/j.jaad.2015.06.063 PubMed
- [36] Katya L Harfmann et al.. Clin Obstet Gynecol. 2015. Hair loss in women. doi:10.1097/GRF.0000000000000081 PubMed
- [37] Dimitrios Ioannides et al.. Curr Probl Dermatol. 2015. Female pattern hair loss. doi:10.1159/000369404 PubMed
- [38] C M Salavastru et al.. Hautarzt. 2013. [Spironolactone in dermatological treatment. On and off label indications]. doi:10.1007/s00105-013-2597-y PubMed
- [39] Lauren L Levy et al.. Int J Womens Health. 2013. Female pattern alopecia: current perspectives. doi:10.2147/IJWH.S49337 PubMed
- [40] R Sinclair et al.. Br J Dermatol. 2011. Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. doi:10.1111/j.1365-2133.2011.10630.x PubMed
- [41] Anosha Yazdabadi et al.. Australas J Dermatol. 2011. Treatment of female pattern hair loss with the androgen receptor antagonist flutamide. doi:10.1111/j.1440-0960.2010.00735.x PubMed
- [42] Deepani Rathnayake et al.. Dermatol Clin. 2010. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. doi:10.1016/j.det.2010.03.011 PubMed
- [43] Deepani Rathnayake et al.. Skinmed. 2010. Use of spironolactone in dermatology. PubMed
- [44] Anosha Yazdabadi et al.. Australas J Dermatol. 2009. Successful treatment of female-pattern hair loss with spironolactone in a 9-year-old girl. doi:10.1111/j.1440-0960.2009.00517.x PubMed
- [45] Francisco M Camacho-Martínez. Semin Cutan Med Surg. 2009. Hair loss in women. doi:10.1016/j.sder.2009.01.001 PubMed
- [46] . Harv Womens Health Watch. 2009. Treating female pattern hair loss. Noticeable hair loss can be deeply distressing. Here are some medical treatments that may help. PubMed
- [47] Noah Scheinfeld. Dermatol Online J. 2008. A review of hormonal therapy for female pattern (androgenic) alopecia. PubMed
- [48] Carlijn Hoedemaker et al.. Australas J Dermatol. 2007. Treatment of female pattern hair loss with a combination of spironolactone and minoxidil. doi:10.1111/j.1440-0960.2007.00332.x PubMed
- [49] Matti Hannuksela. Duodecim. 2006. [The treatment of female pattern hair loss]. PubMed
- [50] Elise A Olsen et al.. J Am Acad Dermatol. 2005. Evaluation and treatment of male and female pattern hair loss. doi:10.1016/j.jaad.2004.04.008 PubMed
- [51] R Sinclair et al.. Br J Dermatol. 2005. Treatment of female pattern hair loss with oral antiandrogens. doi:10.1111/j.1365-2133.2005.06218.x PubMed
- [52] Rodney Sinclair. J Am Acad Dermatol. 2005. Chronic telogen effluvium: a study of 5 patients over 7 years. doi:10.1016/j.jaad.2004.05.040 PubMed
إخلاء مسؤولية FDA: لم تُقيَّم هذه البيانات من قبل إدارة الغذاء والدواء (FDA). لا تهدف المنتجات والمعلومات الواردة في هذا الموقع إلى تشخيص أو علاج أو شفاء أو الوقاية من أي مرض. تستند تقييمات الأدلة المعروضة إلى تحليلنا للأبحاث المحكّمة المنشورة ولا تُشكّل نصيحة طبية. استشر مقدم الرعاية الصحية دائماً قبل البدء بأي نظام مكملات.